Summit’s AGM statement highlights the strong progress the group has made during the last twelve months. The pipeline has progressed and a successful NASDAQ initial public offering completed. The group’s lead programmes, SMT C1100 for Duchenne Muscular Dystrophy (DMD) and SMT 19969 for C. difficile infection, are both on track to deliver data in H2 2015. The second half of the year promises to generate significant news flow and we believe the potential upside in Summit is substantial. We remain upbeat about Summit’s future prospects and look forward to data from both programmes.